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Abstract
Objective. To assess the pain prevalence, pain in-
tensity, and pain medication use in older patients
with a diagnosed subtype of dementia, mild cogni-
tive impairment (MCI), or subjective cognitive im-
pairment (SCI).
Design. Cross-sectional.
Setting. Outpatient memory clinics.
Subjects. In total, 759 patients with Alzheimer’s dis-
ease (AD), vascular dementia, mixed AD and vascu-
lar pathology (MD), frontotemporal dementia,
dementia with Lewy Bodies, MCI, or SCI.
Methods. Self-reported presence and intensity of
pain, prescribed medication, and related descriptive
variables were given for each group. To compare
groups on prevalence of pain, logistic regression
analyses were adjusted for age, gender, and mood.
Differences in pain intensity were tested using a
Kruskall-Wallis test, and differences in analgesic
use with chi-square analyses.
Results. Pain prevalence ranged from 34% in MD to
50% in SCI. AD (odds ratio [OR] 5 0.56, 95% confi-
dence interval [CI] 5 0.34–0.93) and MD (OR 5 0.45,
CI 5 0.20–0.98) patients were less likely to report
pain than SCI patients. The self-reported pain inten-
sity did not differ between groups. In total, 62.5% of
patients did not use any analgesic medication des-
pite being in pain, which did not differ significantly
between groups.
VC 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 920
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Conclusion. Outpatient memory clinic patients with
mild to moderate AD and MD are less likely to report
pain than patients with SCI. No difference in self-
reported pain intensity was present. The high per-
centage of patients with and without dementia who
do not use analgesics when in pain raises the ques-
tion of whether pain treatment is adequate in older
patients.
Key Words. Pain; Dementia; Alzheimer’s Disease;
Pain Treatment
Introduction
The worldwide aging of the population is invariably
associated with an increase in the prevalence of aging-
associated conditions, including chronic painful condi-
tions [1]. As a consequence, a significant increase in the
number of older adults suffering from chronic pain can
be anticipated. The prevalence of painful conditions in
older individuals has been estimated to be as high as
50% [2]. The impact of this increase in pain prevalence
may be substantial as pain has been associated with
numerous comorbid problems including an increased
risk of falls [3], neuropsychiatric symptoms (e.g., anxiety
and depression) [4], and a lower quality of life [5]. Aging
is also an important risk factor for the development of
dementia [6]. Studies have demonstrated that in older
individuals with dementia, the prevalence of chronic
painful conditions may be comparable with that of indi-
viduals without dementia [7].
Until recently, research has focused on pain in individu-
als with dementia without specifying the subtype of
dementia or included only individuals with Alzheimer’s
disease (AD) [8]. However, it has been suggested that
the experience of pain may differ between dementia
subtypes [8]. Studies focusing on patients with AD have
revealed mixed results, showing diminished [9–11], un-
altered [12], or even potentially increased pain experi-
ence [13,14] compared with healthy controls. Pain
experience may be reduced in frontotemporal dementia
(FTD) compared with healthy controls [15]. Studies on
the association between pain and vascular dementia
(VaD) and mixed AD and vascular pathology, referred to
as mixed dementia (MD), suggest that individuals with
VaD and MD experience the pain more intensely or
have more pain locations than older individuals with AD
and controls [16–18]. No studies have focused on the
experience of pain in dementia with Lewy Bodies (DLB).
However, considering the typical neuropathology of
DLB, one would expect that the pain experience is simi-
lar to that of older individuals with AD [19].
The aim of our study was to provide the first overview of
pain prevalence in older individuals suffering from differ-
ent dementia subtypes, namely AD, VaD, MD, FTD,
DLB, and mild cognitive impairment (MCI), as well as
subjective cognitive impairment (SCI). First, we will as-
sess the prevalence of pain, pain intensity, and the use
of analgesic medication. Second, we will assess
whether pain prevalence differs between clinical groups
(i.e., dementia subtypes and MCI) and a control group
of elderly individuals with subjective memory complaints
adjusted for demographic variables and mood. It is
hypothesized that pain prevalence is lower in older
adults with AD than in older adults with VaD, MD, MCI,
or SCI. No difference in pain prevalence is expected be-
tween AD, FTD, and DLB.
Methods
Study Design
This cross-sectional study included patients recruited
from three outpatient memory clinics in Amsterdam,
Amstelveen, and Zutphen, the Netherlands. All patients
were referred to a memory clinic with cognitive com-
plaints. Patients were included in this study if they were
older than age 60 years and excluded if they were pri-
marily mentally disabled (e.g., Down syndrome), had a
primary psychiatric disorder based on clinical diagnosis,
had insufficient command of the Dutch language, or if
they indicated verbally and/or nonverbally that they did
not wish to participate despite earlier consent. Data col-
lected conform with the declaration of Helsinki. The
data collection took place prospectively between 2014
and 2015 in Amsterdam and Amstelveen. In Zutphen,
existing clinical data, which were collected between
2004 and 2015, were used for all eligible patients.
The cohort of Amsterdam/Amstelveen consisted of 212
patients with a diagnosis of AD, MD, VaD, FTD, DLB,
MCI, or SCI. Subsequently, patients were excluded for
not completing the pain assessment (N¼15). The base-
line sample of Zutphen consisted of 660 patients with a
diagnosis of interest. Subsequently, patients (N¼ 93)
were excluded for missing pain data, leaving 567
patients available for analyses. In order to reliably inter-
pret the self-reported presence and intensity of pain,
patients with an Mini-Mental State Examination (MMSE)
score lower than 12, indicating severe cognitive impair-
ment, were excluded as well (N¼5) [20].
The clinical diagnosis of dementia was based on con-
sensus within a multidisciplinary team using the National
Institute of Neurological and Communicative Disorders
and Stroke (NINCDS) and the Alzheimer’s Disease and
Related Disorders Association (ADRDA) criteria for de-
mentia due to Alzheimer’s disease [21], the National
Institute of Neurological Disorders and Stroke (NINDS)
Association Internationale pour la Recherche et
l’Enseignement en Neurosciences (AIREN) criteria for
vascular dementia [22], the revised criteria for FTD [23],
and the revised criteria for DLB [24]. The clinical diagno-
sis of dementia included computed tomography (CT) or
magnetic resonance imaging (MRI) as part of the stand-
ard diagnostic process. MCI was diagnosed according
to National Institute on Aging and Alzheimer’s
Association (NIA AA) criteria [25]. Finally, the presence
of SCI was established in those patients who visited the
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clinic for subjective complaints and did not show any in-
dication of cognitive impairment or a psychiatric or
neurological disorder that could account for their
complaints.
Pain Assessment
In Amsterdam and Amstelveen, pain was assessed
using the Brief Pain Questionnaire–short form (BPI) [26].
The BPI is used to assess the presence of pain and the
pain intensity. The presence of pain was assessed by
asking the patients whether they had pain today other
than everyday kinds of pain (e.g., minor headaches,
sprains, and toothaches). Pain intensity was assessed
by asking the patients to rate the intensity of their pain
on average and in the last 24 hours. Pain intensity is
scored on an 11-point scale, with higher numbers indi-
cating more severe pain.
In Zutphen, pain was assessed in two ways. The first
assessment took place during a general physical exam-
ination as part of the clinical diagnostic procedure, in
which all patients were questioned about their physical
complaints, including pain complaints. Pain intensity
was assessed using an 11-point numerical rating scale,
which was identical to that used in Amsterdam and
Amstelveen.
Mood
Mood was assessed using the Geriatric Depression
Scale–short form [27]. The GDS is a 15-item self-report
questionnaire with a maximum score of 15 points. The
GDS has been validated against the ICD-10 and DSM-
IV diagnosis of depression in older individuals, both with
and without dementia, and has shown acceptable valid-
ity and specificity in individuals with an MMSE score of
15 points or higher [28–30].
Education
Education was scored with an adapted version of the
Verhage seven-point ordinal rating scale [31]. The ori-
ginal scale is: 1 ¼ less than primary education, 2 ¼
completed primary education, 3 ¼ primary education
with incomplete secondary education, 4 ¼ complete
secondary education, 5 ¼ four years of secondary edu-
cation, 6 ¼ pre-university education and/or higher voca-
tional education, and 7 ¼ academic degree. In the
adapted version, the first four points have been taken
together to represent lower education, while the other
points remain unchanged.
Medication Use
Medication use was assessed by using a list of the pre-
scribed medication provided by the pharmacy or pri-
mary physician. For the current study, only medication
that conformed to the Anatomical Therapeutic Chemical
classification system—N02 analgesics, N03 anticonvul-
sants, N05 psycholeptics, N06A antidepressants, and
M01A nonsteroidal anti-inflammatory drugs (NSAIDs)—
were included. The NSAID medication was added to the
analgesics to create a single analgesic medication vari-
able. In addition, an additional analgesic variable was
computed that included analgesics and all types of
medication that may be used as off-label pain medica-
tion (i.e., N02 analgesics, N03 anticonvulsants, N05
psycholeptics, N06A antidepressants, and M01A
NSAIDs). The use of the included medications was
dichotomized into present or absent.
Chronic Diseases
Information about the presence of chronic diseases was
obtained from the primary physician and from the med-
ical status. The chronic diseases were grouped into car-
diovascular disease (CVD) and diabetes. The
cardiovascular diseases include coronary artery dis-
eases, atrial fibrillation, congestive heart failure, cardio-
myopathy, transient ischemic attack, cardiovascular
accident, and hypertension. The presence of CVD and
diabetes was dichotomized. For the analyses, the pres-
ence/absence of diabetes and the presence/absence of
CVD were used.
Statistical Analyses
Descriptive data are presented for all dementia groups,
MCI, and SCI. The FTD and DLB group were excluded
from further analyses due to a limited sample size.
Differences in demographic variables, pain intensity, and
medication use between the dementia subtypes (AD,
MD, and VaD), MCI, and SCI were assessed using chi-
square or Kruskall-Wallis tests. In the case of a signifi-
cant group effect with Kruskall-Wallis tests, post hoc
Dunn-Bonferroni tests were computed.
Logistic regression analyses were performed to test the
associations between dementia subtype, MCI, and SCI
and “presence of pain,” adjusted for demographic variables
and mood. In the first logistic regression analysis, SCI was
used as the reference group, and in the second AD was
the reference group. Education level was not correlated
with the presence of pain and was therefore not included
as possible confounder. Statistical analyses were per-
formed using SPSS 21.0 software. Results were consid-
ered statistically significant at a P value of less than 0.05.
Results
Patient Characteristics
In total, 759 patients were included in the present study,
with a median age of 79 years (interquartile range [IQR]
¼ 75–84 years). The groups differed on age (Kruskal-
Wallis H(4)¼ 60.69, P< 0.001). Post hoc analyses indi-
cated that patients with MD were older than patients
with AD, VaD, MCI, and SCI and that in addition
patients with AD and MCI were older than patients with
SCI. Half of the patients were female, which did not dif-
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differed significantly between groups (Kruskal-Wallis
H(4)¼282.46, P< 0.001), and post hoc Dunn-
Bonferroni analyses indicated that individuals with MCI
and SCI had a significantly higher MMSE performance
than each of the dementia groups. The dementia
groups did not differ significantly with regard to MMSE
score. Overall, the number of depressive symptoms was
low (2.0 points, IQR ¼ 1–4), although the GDS score
did differ between groups (Kruskal-Wallis H(4)¼ 23.61,
P< 0.001). Patients with AD and MCI reported fewer
depressive symptoms than patients with VaD and MD.
Patient characteristics are presented in Table 1 and
Supplementary Table S1 for FTD and LBD.
Pain Characteristics
The pain characteristics are presented in Table 2 and
Supplementary Table S2 for FTD and LBD. No statistical
difference in self-reported pain intensity was observed
between the dementia subtypes, MCI, and SCI.
Pharmacological Pain Treatment
Overall, 37.5% of patients with self-reported pain used
analgesics. The percentage of analgesic medication use
and reporting pain did not differ significantly between
groups. See Figure 1 for an overview. When analgesics
and all possible types of off-label analgesics were com-
bined, 43.4% of patients with pain received potential
pain medication.
In total, 63 (29.7%) patients with an available NRS score
reported a pain intensity of 4 or higher (median¼6.00,
IQR¼5.00–7.00), indicating moderate to severe pain
[32]. Analgesics were used by 55.6% of these patients.
Table 1 Demographic characteristics
AD MD VaD MCI SCI
(N¼282) (N¼53) (N¼ 56) (N¼ 235) (N¼95)
Age, y 80.0 [77.0–84.3] 83.0 [80.0–87.0] 78.0 [75.0–82.8] 79.0 [74.0–83.0] 76.0 [70.0–81.0]
Female, No. (%) 175 (62.1) 29 (54.7) 26 (46.4) 129 (54.9) 56 (58.9)
Education level (1–4) 1 [1–2] 2 [1–3] 2 [1–3] 2 [1–3] 2 [1–3]
MMSE (0–30) 23.0 [19.0–25.0] 22.0 [19.0–25.0] 23.0 [21.0–26.0] 27.0 [25.0–28.0] 28.0 [27.0–29.0]
GDS (0–15) 2.0 [1.0–3.0] 3.0 [2.0–5.0] 3.0 [2.0–5.0] 2.0 [1.0–3.0] 2.0 [1.0–4.0]
Comorbidity
CVD present, No. (%) 163 (57.8) 42 (80.8) 44 (78.6) 156 (66.7) 61 (64.2)
Diabetes present, No. (%) 43 (15.2) 14 (26.9) 8 (14.3) 47 (20.1) 16 (16.8)
Values are presented as median [interquartile range] or as stated.
AD ¼ Alzheimer’s disease; CVD ¼ cardiovascular disease; GDS ¼ Geriatric Depression Scale; MCI ¼ mild cognitive impairment;
MD ¼ mixed Alzheimer’s and vascular pathology; MMSE ¼ Mini-Mental State Examination; SCI ¼ subjective cognitive impair-
ment; VaD ¼ vascular dementia.
Table 2 Pain characteristics
AD MD VaD MCI SCI
N (N¼282) (N¼ 53) (N¼56) (N¼235) (N¼ 95)
Pain present 759 97 (34.4) 18 (34.0) 25 (44.6) 96 (40.9) 47 (49.5)
Pain and analgesic use 757 120 (42.6) 28 (54.9) 30 (52.6) 122 (52.1) 55 (57.9)
Pain intensity (0–10), median (IQR)* 212 0 [0–3.5] 0 [0–5] 0 [0–5] 1 [0–5.5] 1 [0–5]
Chronic pain (90 d)† 175 10 (22.2) 7 (20.0) 2 (22.2) 20 (40.0) 6 (27.3)
Medication use, No. (%)
Analgesics 750 55 (19.7) 15 (30.0) 20 (35.7) 60 (25.9) 26 (27.4)
Antidepressants 753 11 (3.9) 7 (13.5) 3 (5.4) 12 (5.2) 8 (8.4)
Anticonvulsants 753 7 (2.5) 0 4 (7.1) 5 (2.1) 4 (4.2)
Psycholeptics 753 14 (5.0) 8 (15.4) 1 (1.8) 6 (2.6) 5 (5.3)
Values are presented as No. (%) or as stated.
AD ¼ Alzheimer’s disease; MCI ¼ mild cognitive impairment; MD ¼ mixed Alzheimer’s and vascular pathology; SCI ¼ subjective
cognitive impairment; VaD ¼ vascular dementia.
*Not all patients in Zutphen were asked to rate their pain intensity.
†Pain chronicity has not been assessed in Zutphen.
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This percentage increased to 65.1% when possible off-
label analgesics were also included.
Difference in Pain Prevalence Between Dementia
Subtypes (i.e., AD, MD, VaD), MCI, and SCI
Table 3 shows that the full model was the best predict-
ive model for pain prevalence (Nagelkerke R2¼ 0.05, v2
(7, N¼ 673)¼ 23.61, P¼ 0.001). Patients with AD and
MD have, respectively, chances that are 0.56 and 0.45
times lower of reporting being in pain than patients with
SCI.
Difference in Pain Prevalence Between Dementia
Subtypes (i.e., MD, VaD), MCI, SCI, and AD
In order to assess whether the presence of pain differed
between AD and the other subgroups, AD was used as
the reference group. Table 3 shows that the full model
was the best predictive model (Nagelkerke R2¼0.05, v2
(7, N¼ 673)¼ 23.61, P¼0.001). Patients with SCI are
1.79 times more likely to report a painful condition than
patients with AD. The presence of pain did not signifi-
cantly differ between AD and any of the other partici-
pant groups.
Discussion
The goal of the present study was to provide an over-
view of the prevalence and intensity of pain and the use
of analgesic medication in patients with a diagnosis of
AD, VaD, MD, FTD, DLB, or other age-related cognitive
complaint, that is, mild cognitive impairment (MCI) and
subjective cognitive impairment (SCI). In addition, differ-
ences in the self-reported presence of pain were
assessed for each of the dementia subtypes; MCI and
SCI were adjusted for demographic variables and
mood.
Our results indicate that the self-reported prevalence of
pain is lower in patients with AD and MD than in
patients with SCI. The observed prevalence of pain for
AD (34.4%) and MD (34.0%) is consistent with earlier
studies in outpatients with AD (34–35%) [33–35] and
MD (31.7%) [34]. However, contrary to our expectations,
we did not find a significant difference in the prevalence
of pain between AD and VaD. A higher prevalence of
pain in VaD was expected based on the (neuro)pathol-
ogy of this disorder. In VaD, the presence of vascular
lesions in the brain that compromise white matter tracts
may increase the presence and experience of pain due
to deafferentiation [19]. In addition, pain is known to be
an important comorbidity in patients with cardiovascular
problems [36]. To date, only a limited number of studies
have addressed pain in patients with vascular dementia.
No pain studies have been performed in outpatients
with VaD. In nursing homes, the prevalence of pain
does not seem to differ significantly between VaD and
other subtypes of dementia [16]. However, patients with
VaD and MD do report more painful locations than
patients with AD [16], and a higher pain affect in VaD
compared with patients without dementia has also been
reported [18,37].
Although the relevance of studying pain in older individ-
uals with cognitive impairment has been known for
25 years, the treatment and detection of pain in this pa-
tient group are still topics of debate [38].
Analgesic medication use for patients who indicated
that they were in pain varied between 27.8% for MD
and 60.0% for VaD, but this difference did not reach
significance. In total, 29.7% of patients reported moder-
ate to severe pain, of whom 55.6% used analgesics.
Earlier research has suggested that there may be
suboptimal treatment of pain in elderly people with de-
mentia [8]. In the current study population, the degree
of suboptimal treatment appears to be limited. Still, al-
most one in three patients report clinically relevant pain,
of whom only half receive treatment. These numbers
cannot be exclusively explained by problems with the
assessment of pain in dementia as it even occurs when
a person is correctly identified to experience pain [7].
One explanation for the apparent suboptimal treatment
of pain is that not all types of pain are treated with anal-
gesics. In 2006, a taskforce of the European Federation
of Neurological Societies (EFNS) published a compre-
hensive review addressing the treatment of neuropathic
pain, in which they presented evidence for the success-
ful pain-relieving capabilities of antidepressants, anti-epi-
leptics, and anticonvulsants for different types of
neuropathic pain [3]. Still, even after we incorporated all
these types of medication and analgesics into one pain
medication score, the idea of an apparent suboptimal
treatment of pain remains as 34.9% of participants with
moderate to severe pain intensity do not receive any of
these types of medication. Another possible explanation
Figure 1 Analgesic use in patients reporting pain.
Both absolute numbers and proportion of patients that
use analgesics when suffering from pain are presented.
AD ¼ Alzheimer’s disease; MCI ¼ mild cognitive impair-
ment; MD ¼ mixed Alzheimer’s and vascular pathology;
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for the low analgesic use may be the physicians’ fear of
the negative effects of polypharmacy, pharmacokinetic
changes, and pharmacodynamic changes in older
patients [39,40]. These fears may be warranted given
that, especially for moderate to severe pain, evidence
concerning the safety and efficiency of pharmacological
treatments in older adults is scarce [41]. This may lead
to physicians being more inclined to prescribe nonphar-
macological interventions, which were not included in
the present study.
Limitations
One of the limitations of our study is that the control
group without dementia is not a true control group. The
patients in the SCI group were all referred to the out-
patient memory clinic for cognitive screening after hav-
ing reported cognitive complaints. Only patients in
whom these cognitive complaints were not the result of
underlying psychiatric conditions, primary neurological
disorders, or chance findings were included. In addition,
all adults were cognitively intact, in that they did not
show any evidence of cognitive impairment on extensive
neuropsychological testing. Nonetheless, these individu-
als may not form a truly accurate representation of the
normal population. Previous research has also found
that patients with SCI are younger than patients with
MCI or dementia [42]. The SCI group in the current
study has a higher pain prevalence than AD and MD
despite being younger. The reasons for the subjective
experience of cognitive impairment in SCI are known to
be varied, including, among others, sleep disorders,
medical disorders, and substance use [42]. These fac-
tors are also known to be associated with pain; for ex-
ample, sleep disturbances are positively associated with
pain sensitivity and pain tolerance [43–45] and may ex-
plain the higher prevalence of pain in the SCI group. In
addition, depressive symptoms may play a role as these
symptoms share multiple interactions with pain [46,47].
These symptoms may have influenced our study
findings. However, the self-reported intensity of depres-
sive symptoms was relatively low in our sample and
was controlled for in the analyses. The validity of the
GDS is reduced, much like other self-report question-
naires, in patients with severe cognitive impairment.
Nonetheless, given the relatively high median MMSE
score in the current sample, it is unlikely that the validity
of the GDS is significantly compromised. Finally, patients
were not questioned about the potential conditions for
which medication was prescribed; although we were
unable to determine the reason for prescribing the po-
tential analgesic medication, even after including these
types of medication, the notion of an apparent subopti-
mal pain treatment in older patients persisted.
Due to the small number of patients, the FTD and DLB
subgroups were not included in the analyses. Still, it is
important to present the data concerning the pain char-
acteristics of these groups. To date, studies concerning
pain in these subtypes of dementia have proven scarce,
which is likely due to their low prevalence (for FTD) or
the difficulty in correctly diagnosing the condition (for
DLB and potentially FTD). Presenting these data despite
small numbers may enable future researchers to pool
the results with other studies in which these subtypes
were present in insufficient numbers to be included in
the analysis.
Conclusions
The prevalence of self-reported pain in outpatient mem-
ory clinic patients with the dementia subtypes AD, VaD,
and MD, or MCI or SCI, ranges widely. In a mild to
moderate state of dementia, older patients with AD and
MD are less likely to report suffering from pain than
patients with SCI. The self-reported pain intensity does
not appear to differ between the dementia subtypes,
MCI, and SCI. Overall, more than half of the patients,
both with and without dementia, do not use analgesic
medication when in pain. Further research is necessary
Table 3 Association between presence of pain and clinical groups with SCI or AD as reference
(N¼ 674)
SCI Reference Group AD Reference Group
OR 95% CI P OR 95% CI P
Group AD 0.56 0.34–0.93 0.02 1.00
MD 0.45 0.20–0.98 0.05* 0.80 0.40–1.60 0.48
VaD 0.69 0.34–1.41 0.31 1.24 0.66–2.33 0.51
MCI 0.70 0.42–1.15 0.16 1.25 0.86–1.81 0.25
SCI 1.00 1.79 1.08–2.98 0.02
Nagelkerke R2 0.05** 0.05**
Adjusted for age, sex, and mood.
AD ¼ Alzheimer’s disease; MCI ¼ mild cognitive impairment; MD ¼ mixed Alzheimer’s and vascular pathology; SCI ¼ subjective
cognitive impairment; VaD ¼ vascular dementia.
*P<0.05.
**P<0.001.








edicine/article-abstract/19/5/920/3977944 by Vrije U
niversiteit Am
sterdam
 user on 22 July 2020
to determine whether pain treatment is adequate in
older patients.
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